Novartis' Remibrutinib Gains FDA Approval for Chronic Spontaneous Urticaria
Novartis received FDA approval for Rhapsido (remibrutinib), the first oral BTK inhibitor for treating adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamines, offering a new, fast-acting, and safe treatment option without the need for injections or lab monitoring.